Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + CHOP in Untreated Intermediate/High Grade NHL
NCT00005959Phase 2Unknown
- Sponsor
- Amgen
- Start
- Dec 1999
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in non-Hodgkin lymphoma (NHL), sponsored by Amgen. Primary endpoint: Overall Response Rate. Status: unknown.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00005959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005959.